Low-grade Lymphoproliferative Disorders (CLL, HCL, T-PLL) – Adult

**PATIENT PRESENTATION**

- **Untreated – all stages**
  - CLL
  - HCL/T-PLL

- **Prior therapy**
  - CLL
  - HCL

**TREATMENT**

- **Standard of care:**
  - Non-Del(17p) and/or TP53-mutated:
    - Acalabrutinib (with or without obinutuzumab)
    - Zanubrutinib
    - Ibrutinib
    - Venetoclax plus obinutuzumab
  - Del(17p) and/or TP53-mutated:
    - Acalabrutinib (with or without obinutuzumab)
    - Zanubrutinib
    - Ibrutinib

- **Relapsed/refractory non-Del(17p) and/or TP53-mutated:**
  - Acalabrutinib (with or without rituximab)
  - Zanubrutinib
  - Ibrutinib
  - Venetoclax and rituximab

- **Relapsed Del(17p) and/or TP53-mutated:**
  - Acalabrutinib (with or without rituximab)
  - Zanubrutinib
  - Ibrutinib
  - Venetoclax (with or without rituximab)

- **Discuss Goal Concordant Care (GCC) with patient or if clinically indicated, with Patient Representative**

**SURVEILLANCE**

- **Surveillance as per treatment plan**

### Low-grade Lymphoproliferative Disorders

**Disclaimers:**

- This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

- **Note:** Consider Clinical Trials as treatment options for eligible patients. Leukemia patients should be referred and treated at a comprehensive cancer center.

**Definitions:**

- CLL = chronic lymphocytic leukemia
- HCL = hairy cell leukemia
- IGVH = immunoglobulin heavy-chain variable-region
- T-PLL = T-cell prolymphocytic leukemia

**References:**

1. Age ≥ 18 years
2. See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice
3. Consider MD Anderson approved biomarkers
4. GCC should be initiated by the Primary Oncologist. If Primary Oncologist is unavailable, Primary Team/Attending Physician to initiate GCC discussion and notify Primary Oncologist. Patients, or if clinically indicated, the Patient Representative should be informed of therapeutic and/or palliative options. GCC discussion should be consistent, timely, and re-evaluated as clinically indicated. The Advance Care Planning (ACP) note should be used to document GCC discussion. Refer to GCC home page (for internal use only).

**Department of Clinical Effectiveness V8**

Approved by The Executive Committee of the Medical Staff 05/16/2023
SUGGESTED READINGS


MD Anderson Institutional Policy #CLN1202 - Advance Care Planning Policy

Advance Care Planning (ACP) Conversation Workflow (ATT1925)


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.
Low-grade Lymphoproliferative Disorders
(CLL, HCL, T-PLL) – Adult

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This practice algorithm is based on majority expert opinion of the Leukemia Center Faculty workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads
Alessandra Ferrajoli, MD (Leukemia)
Hagop Kantarjian, MD (Leukemia)
Farhad Ravandi-Kashani, MD (Leukemia)
William Wierda, PhD, MD (Leukemia)

Workgroup Members
Yesid Alvarado, MD (Leukemia)
Michael Andreuff, PhD, MD (Leukemia)
Kapil Bhalla, MD (Leukemia)
Gautam Borthakur, MBBS (Leukemia)
Prithviraj Bose, MD (Leukemia)
Jan Burger, MD (Leukemia)
Naval Daver, MD (Leukemia)
Courtney DiNardo, MD (Leukemia)
Wendy Garcia, BS*
Guillermo Garcia-Manero, MD (Leukemia)
Ghayas Issa, MD (Leukemia)
Elias Jabbour, MD (Leukemia)
Nitin Jain, MBBS (Leukemia)
Tapan Kadia, MD (Leukemia)
Michael Keating, MD (Leukemia)
Marina Konopleva, PhD, MD (Leukemia)
Steven Kornblau, MD (Leukemia)
Lucia Masarova, MD (Leukemia)
Deborah McCue, PharmD (Pharmacy Clinical Programs)
Guillermo Montalban-Bravo, MD (Leukemia)
Maro Ohanian, DO (Leukemia)
Naveen Penmaraju, MD (Leukemia)
Koji Sasaki, MD (Leukemia)
Nicholas Short, MD (Leukemia)
Koichi Takahashi, MD (Leukemia)
Philip Thompson, MBBS (Leukemia)
Srdan Verstovsek, MD (Leukemia)
Mary Lou Warren, DNP, APRN, CNS-CC*
Musa Yilmaz, MD (Leukemia)

* Clinical Effectiveness Development Team